经肛全直肠系膜切除术后的肿瘤学结局:美国经验
这项多中心回顾性观察研究纳入美国8家三级医疗中心2011至2020年间391例连续的原发性直肠癌经肛全直肠系膜切除术(taTME)病例,分析肿瘤学结局。中位随访30.7个月,局部复发9例(2.5%),3年估计疾病复发率19%(CI 15-25%),3年估计总生存率90%(CI 87-94%)。结论认为在经验丰富术者于经验丰富转诊中心实施时,taTME的肿瘤学安全性和围术期获益得到证实。
要点
- 391例taTME病例中,TME标本完整或近完整占94.5%,环周切缘阳性率2.0%,远端切缘阳性率0.3%。
- 中位随访30.7个月,局部复发9例(2.5%),3年估计疾病复发率19%(CI 15-25%)。
- 3年估计总生存率90%(CI 87-94%),结论认为在经验丰富术者与转诊中心实施时肿瘤学安全性获证实。
核心结论
- 这项大型多中心研究证实,在经验丰富术者于经验丰富转诊中心实施时,taTME用于直肠癌具有肿瘤学安全性和围术期获益。
研究设计与样本
- 多中心回顾性观察研究,纳入美国8家三级医疗中心2011至2020年间所有连续的原发性直肠癌taTME病例,共391例。
主要发现
- 中位年龄57岁(IQR:49,66),男性占68%,中位BMI为27.4(IQR:24.1,31.0)。
- TME标本完整或近完整占94.5%,环周切缘阳性率2.0%,远端切缘阳性率0.3%。
- 采用反向Kaplan-Meier估计的中位随访时间为30.7个月(CI 28.1-33.8),未考虑竞争风险的局部复发9例(2.5%)。
- 3年估计疾病复发率为19%(CI 15-25%),3年估计总生存率为90%(CI 87-94%)。
临床怎么用
- 原文结论认为,在经验丰富术者于经验丰富转诊中心实施时,taTME用于直肠癌的肿瘤学安全性和围术期获益得到证实。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: The benefits and short-term outcomes of transanal total mesorectal excision (taTME) for rectal cancer have been demonstrated previously, but questions remain regarding the oncologic outcomes following this challenging procedure. The purpose of this study was to analyze the oncologic outcomes following taTME at high-volume centers in the USA. METHODS: This was a multicenter, retrospective observational study of 8 tertiary care centers. All consecutive taTME cases for primary rectal cancer performed between 2011 and 2020 were included. Clinical, histopathologic, and oncologic data were analyzed. Primary endpoints were rate of local recurrence, distal recurrence, 3-year disease recurrence, and 3-year overall survival. Secondary endpoints included perioperative complications and TME specimen quality. RESULTS: A total of 391 patients were included in the study. The median age was 57 years (IQR: 49, 66), 68% of patients were male, and the median BMI was 27.4 (IQR: 24.1, 31.0). TME specimen was complete or near complete in 94.5% of cases and the rates of positive circumferential radial margin and distal resection margin were 2.0% and 0.3%, respectively. Median follow-up time was 30.7 months as calculated using reverse-KM estimator (CI 28.1-33.8) and there were 9 cases (2.5%) of local recurrence not accounting for competing risk. The 3-year estimated rate of disease recurrence was 19% (CI 15-25%) and the 3-year estimated overall survival was 90% (CI 87-94%). CONCLUSION: This large multicenter study confirms the oncologic safety and perioperative benefits of taTME for rectal cancer when performed by experienced surgeons at experienced referral centers.
引用
- Zewde MG, Peyser DK, Yu AT, et al. Oncologic outcomes following transanal total mesorectal excision: the United States experience. Surg Endosc. 2024. PMID: 38782828. doi:10.1007/s00464-024-10896-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。